Trial Profile
Post-Authorization Safety Study: Cohort Event Monitoring for Dengvaxia, CYD-TDV Dengue Vaccine
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs CYD TDV (Primary)
- Indications Dengue
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi Pasteur
- 03 Jan 2023 Planned End Date changed from 18 Oct 2024 to 1 Jul 2024.
- 03 Jan 2023 Planned primary completion date changed from 18 Oct 2024 to 1 Jul 2024.
- 10 Jan 2020 Planned End Date changed from 18 Dec 2024 to 18 Oct 2024.